Spero Therapeutics
NASDAQ: SPROCambridge, US · Founded 2013 · Delaware corporation · 6 known investors
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease. It focuses on immune signaling pathways involved in inflammation and fibrosis, with potential applications across additional immune-mediated conditions.
Biotech
Founders & leadership
Spero Therapeutics was founded in 2013 by Ankit Mahadevia.
AM
Ankit MahadeviaFounder
SG
Stephen GarbaczExecutive
Board
JF
RH
CB
Casper BreumBoard director
VG
Vikas GoyalBoard director
PV
Patrick VinkBoard director
MD
Milind DeshpandeBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$92.2M disclosed across 3 of 4 rounds · 2017–2026
▶$9MraisedNov 2022 · 1 investors · BiotechnologyRule 506(b)
▶$9MraisedNov 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Milind DeshpandeDirector
- Kamal HamedExecutive Officer
- Scott JacksonDirector
- Tamara JosephExecutive Officer
- Kathleen TregoningDirector
- Patrick VinkDirector
- Satyavrat ShuklaExecutive Officer
- Timothy KeutzerExecutive Officer
- John C. Pottage, Jr.Director
- Ankit MahadeviaExecutive Officer, Director
- Cynthia SmithDirector
- Frank E. ThomasDirector
- Offering amount
- $9M
- Amount sold
- $9M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40MraisedJul 2021 · 1 investors · BiotechnologyRule 506(b)
▶$40MraisedJul 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Milind DeshpandeDirector
- David MelnickExecutive Officer
- Patrick VinkDirector
- Cynthia SmithDirector
- Satyavrat ShuklaExecutive Officer
- Tamara JosephExecutive Officer
- Scott JacksonDirector
- Timothy KeutzerExecutive Officer
- Frank E. ThomasDirector
- Cristina LarkinExecutive Officer
- John C. Pottage, Jr.Director
- Ankit MahadeviaExecutive Officer, Director
- Jean-Francois FormelaDirector
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$43.2MraisedMar 2017 · 11 investors · BiotechnologyRule 506(b)
▶$43.2MraisedMar 2017 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick VinkDirector
- Milind DeshpandeDirector
- Jean-Francois FormelaDirector
- Reza HalseDirector
- Casper BreumDirector
- Ankit MahadeviaExecutive Officer, Director
- Stephen GarbaczExecutive Officer
- Vikas GoyalDirector
- Offering amount
- $43.2M
- Amount sold
- $43.2M
- First sale
- Mar 2017
- Incorporated
- Limited Liability Company, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapSarepta Therapeutics33 shared keywordsSarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.
Spyre Therapeutics31 shared keywordsSpyre Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunology, aiming for more complete disease control, greater durability, and simpler treatment. Its pipeline targets validated mechanisms to treat gastrointestinal and rheumatic conditions in patients.
Solu29 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Seeking Alpha25 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Companies competing with Spero Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Spero Therapeutics do?
- Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease. It focuses on immune signaling pathways involved in inflammation and fibrosis, with potential applications across additional immune-mediated conditions.
- Who founded Spero Therapeutics?
- Spero Therapeutics was founded by Ankit Mahadevia in 2013.
- Who are Spero Therapeutics's investors?
- Spero Therapeutics's investors include HEALTHCARE ROYALTY PARTNERS, MRL Ventures Fund, OUP (Osage University Partners), RA Capital, Alphabet, Atlas Venture.
- How much funding has Spero Therapeutics raised?
- Spero Therapeutics has disclosed $92.2M raised across 3 of its 4 known rounds.
- Where is Spero Therapeutics headquartered?
- Spero Therapeutics is headquartered in Cambridge, US.